Nuwellis, Inc. · NASDAQ:NUWE
Nuwellis — Investor Presentation (November 2026)
24 slides from Nuwellis's investor presentation, Nov 17, 2026
Slide 1: November 2026 Investor Presentation
November 2026 INVESTOR PRESENTATION NASDAQ: NUWE
Slide 2: Forward-Looking Statements
NASDAQ: NUWE Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act, as amended regarding our plans, expectations, beliefs, estimates, goals and ou
Slide 3: Investment Highlights
NASDAQ: NUWE See Appendix for Market Opportunity sources. Investment Highlights 3 Best-in-class ultrafiltration technology Aquadex® is a clinically proven system for precise, predictable fluid removal reducing hospital readmissions and improving outcomes Streamlined solution that is cost-effective,
Slide 4: Fluid Overload Drives Mortality and Hospitalizations
Fluid Overload Drives Mortality and Hospitalizations 4 Higher ICU Mortality Fluid overload is associated with significantly increased 90-day mortality in critically ill ICU patients2 Increased Pediatric Mortality Fluid overload is linked to substantially higher mortality in critically ill children3-
Slide 5: $4.4B Addressable U.S. Market Opportunity
NASDAQ: NUWE Sources: See Appendix $4.4B Addressable U.S. Market Opportunity 5 Nuwellis current platform and future products collectively address a large market opportunity across five segments Critical Care Inpatient HF Outpatient HF Pediatrics Fluid Monitoring $1B $1B $787M $178M $1.4B
Slide 6: Our Solution: Aquadex
6 Our Solution Aquadex® A clinically proven therapy for precise, predictable fluid removal1 Low-volume ultrafiltration designed for critically ill patients Allows controlled fluid removal when diuretics fail or are ineffective Adopted in ICU, cardiac surgery, and pediatric critical care programs 1Pi
Slide 7: Aquadex System: Predictable and Precise Fluid Removal
NASDAQ: NUWE Aquadex System: Predictable and Precise Fluid Removal Filtered blood returns to the patient via the infusion line 5 Blood is taken from the patient via the withdrawal line using proprietary catheter technology 1 The blood is pushed through the filter by the blood pump (0-40 ml per minut
Slide 8: Aquadex System: High-Margin Recurring Revenue Model
NASDAQ: NUWE Aquadex System: High-Margin Recurring Revenue Model 8 One-time CapEx purchase Price point: high-value Flexible acquisition models: purchase, lease or rental Single-use for every treatment High-margin Increasing utilization as adoption spreads Aquadex Console Capital Equipment Disposable
Slide 9: Commercial Execution Demonstrating Broad-Based Growth
NASDAQ: NUWE Commercial Execution Demonstrating Broad-Based Growth 9 Broad Clinical Coverage Pediatric - 26% growth* in pediatric nephrology & critical care Critical Care – 7% growth* in ICU/intensivists & cardiac surgery Heart Failure – 9% growth* in heart failure cardiology *Nine months ended 9/30
Slide 10: Pediatric Leadership Driving Future Growth
NASDAQ: NUWE Pediatric Leadership Driving Future Growth 10 Future Pediatric Product Offering Established adoption creates a foundation for expanded indications and next-generation therapies Installations in 47 Leading U.S. Children’s Hospitals* Established clinical footprint across pediatric critica
Slide 11: Critical Care: Addressing Fluid Overload Following Cardiac Surgery
NASDAQ: NUWE Critical Care: Addressing Fluid Overload Following Cardiac Surgery 11 The Problem Cardiac surgery can require significant fluid administration, contributing to post-operative fluid overload1 1 DeVore A, et al. Curr Treat Opts Cardiovasc Med. 2014; 16(2):283. 2 Bundgaard-Nielsen M, et al
Slide 12: Heart Failure: Breaking the Cycle of Fluid Overload and Readmission
NASDAQ: NUWE Heart Failure: Breaking the Cycle of Fluid Overload and Readmission 12 The Problem Persistent congestion drives repeat hospitalization Aquadex Solution Precise, predictable fluid removal – for patients with fluid overload when diuretics are inadequate 60% Reduction in HF Events at 30 da
Slide 13: Expanding Beyond Fluid Removal into Critical Care Solutions
NASDAQ: NUWE *ClarityPRIME is currently under development and is not FDA cleared. Expanding Beyond Fluid Removal into Critical Care Solutions 13 Leveraging our ICU & pediatric commercial infrastructure to expand into adjacent monitoring and therapy markets Current Commercial Engine Near-term Expansi
Slide 14: Expanding Aquadex Capabilities to Extend Platform Use
NASDAQ: NUWE Technologies and expanded applications described are under development and subject to applicable regulatory requirements. R&D Expanding Aquadex Capabilities to Extend Platform Use 14 SmartView Provides Real-time Insights Pressure IQ Expands Aquadex Performance and Versatility Multiple F
Slide 15: AtriAmp Advances Nuwellis' Expansion Strategy
NASDAQ: NUWE AtriAmp Advances Nuwellis' Expansion Strategy A capital-efficient opportunity to broaden Nuwellis' product portfolio and leverage existing hospital relationships 15 CLINICAL VALUE AtriAmp improves visibility into postoperative arrhythmias in adult and pediatric cardiac surgery patients
Slide 16: Zorro-Flow Expands Nuwellis' Pediatric Cardiorenal Portfolio
NASDAQ: NUWE 1https://www.nature.com/articles/s41372-023-01834-x Zorro-Flow® Expands Nuwellis' Pediatric Cardiorenal Portfolio Exclusive U.S. distribution rights leverage established pediatric hospital relationships to create new recurring revenue opportunities. 16 CLINICAL VALUE A non-invasive urin
Slide 17: ClarityPRIME System Expands Nuwellis into Smart Fluid Monitoring
NASDAQ: NUWE 17 1 Addresses a Critical Need in Cardiac Surgery & Critical Care Enters a High-growth, Underpenetrated Market Fits Directly Into Our Existing Sales Channel Real-time urine output and electrolyte data are essential for early detection of AKI. Targets the emerging automated urine monitor
Slide 18: Introducing Vivian
18 Introducing Vivian Developing our dedicated pediatric solution Currently in development and supported by a $3M NIH grant. Ultra-low ECV (29–67 mL) for neonatal + small-child CRRT Engineered for patients as small as 2.5kg with unique Hematocrit and SVO2 sensor safety features Integrated UF, CVVH,
Slide 19: Established Platform with Multiple Growth Drivers
NASDAQ: NUWE 19 Established Platform with Multiple Growth Drivers Commercial Momentum +13% YTD 2026 revenue growth versus prior-year 72% YTD 2026 gross margin, up from 59% in YTD 2025 Hospital Opportunity ~135 Active hospital accounts Installed in ~10% of target hospitals Significant opportunity to
Slide 20: Target Milestones
NASDAQ: NUWE Target Milestones 20 Target Date | Completed Milestone Q3 2026 | Aug. 2026 Strategic partnership/distribution agreement Q4 2026 | Oct. 2026 Publication of ULTRA-Peds data in Pediatric Nephrology Q4 2026 | Nov. 2026 FDA 510(k) submission for pediatric indication expansion to >5kg (from >
Slide 21: Nuwellis Leadership Team
NASDAQ: NUWE Nuwellis Leadership Team Over 200 years of combined experience in clinical practice and the medical device industry, including major tenures at J&J, Boston Scientific, Medtronic, and Abbott/St. Jude Medical 21 Ryan Marthaler Vice President of Product Marketing and Business Development B
Slide 22: Financial Highlights
NASDAQ: NUWE * See SEC filings for Preferred Stock terms and anti-dilution provisions. Financial Highlights 22 Pediatrics ~50% Revenue Mix $6.6M YTD Q3 26 Heart Failure ~26% Critical Care ~24% 13% YTD 2026 revenue growth versus the prior-year period Capitalization as of September 30, 2026 Common Equ
Slide 23: Contact Details
Contact Details Investor Relations: CORE IR Yvonne Briggs ir@nuwellis.com Media Inquiries: CORE PR Kati Waldenburg media@nuwellis.com
Slide 24: Appendix: Market Size Sources
NASDAQ: NUWE Appendix Market Size Sources Heart Failure – Inpatient Incidence of HF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/ Annual HF Hospitalizations: Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445 Insufficient diuretic response: https://www.ahajournals.org/doi/1